Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2018; 72(1): 47–49. doi:10.14735/amgh201847.

Efficacy of ustekinumab in a patient refractory to other biological treatment

Martin Bortlík  1,2,3, Naděžda Machková  1, Veronika Hrubá1, Martin Lukáš  1, Dana Ďuricová  1, Karin Malíčková  1,4, Zuzana Šerclová  5, Milan Lukáš  1

+ Affiliation


This case report describes a female patient who was diagnosed at the age of 11 with Crohn’s disease with ileocecal and perianal localization. The disease course was progressive, and conventional therapy was ineffective. The patient did not tolerate long-term treatment with anti-TNF antibodies. Next, therapy with an anti-integrin antibody was given, which had some efficacy for the luminal disease, but none for the perianal disease. Therefore, in June, 2017, we initiated therapy with ustekinumab. The patient responded within 6 weeks, with clear improvement of bowel symptoms as well as perianal disease. We have not observed any adverse effects of ustekinumab in this patient.


Crohn’s disease, biologic therapy, ustekinumab

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. Bortlík M. Vývoj léčby IBD v posledních 20 letech. Gastroent Hepatol 2015; 69 (4): 341–350.
2. Lukáš M. Ustekinumab – nová biologická léčba pro pacienty s Crohnovou chorobou. Gastroent Hepatol 2017; 71 (2): 178–180. doi: 10.14735/amgh2017178
3. Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn‘s disease. N Engl J Med 2016; 375 (20): 1946–1960.
4. Státní ústav pro kontrolu léčiv. Podmínky úhrady LP Stelara. [online]. Available from: http: //
5. Sands B. Fistula healing in pivotal studies of ustekinumab in Crohn‘s disease. Presented at:  Digestive Disease Week 2017. May 6–9, 2017.

Credited self-teaching test